COVID-19
Moderna’s mRNA Zika vaccine data is becoming helpful in the development of the COVID-19 vaccine. The company is using the elements to faster the process of producing the vaccine.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
The U.S. Food and Drug Administration granted emergency use authorization to Rutgers’ RUCDR Infinite Biologics for its test that uses saliva.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
In its daily blog about the precautions the company is taking to ensure continued service to the world, Amazon said it will build its own testing facilities for employees.
The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug.
Eli Lilly will begin exploring the use of its rheumatoid arthritis drug Olumiant as a treatment for hospitalized patients with COVID-19. A clinical trial will begin this month and results are expected within the next two months.
The Stanford serology test provides results in two to three days and Stanford Health Care can test 500 samples per day. Know what more it has to offer.
On Thursday, the American Medical Association doubled down on its stance against using off-label medicines like hydroxychloroquine and chloroquine to treat COVID-19 patients.
PRESS RELEASES